Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the
global leader in DNA sequencing and array-based technologies, to advance understanding of the human gut microbiome in
human health and disease.
The partnership will bring together Microba’s high-quality proprietary gut microbiome analysis platform with Illumina’s
revolutionising Next Generation Sequencing tools to generate the accurate metagenomic data researchers require to make
new discoveries.
Focusing activities in Asia Pacific and Japan, the duo will work together to enable research studies that reveal
connections between the microbiome and human health from mental health and Parkinson’s disease to nutrition and sleep.
Such projects wouldn’t be possible without access to the accurate and high-resolution data that Illumina’s methodology
enables, combined with Microba’s analysis.
Microba CEO Mr Blake Wills said the partnership would further accelerate the adoption of gut microbiome profiling for
research into human disease.
“There remains huge potential for research to enhance our understanding of the role the gut microbiome plays in health
and disease states,” he said.
“Combining Microba’s deep analysis capability with Illumina’s advanced technology, this potential is being realised.”
Illumina Vice President and General Manager of Asia Pacific and Japan, Ms Gretchen Weightman, explained that by working
together the companies could rapidly deliver insights and the accessibility of gut microbiome analysis.
“With genomic sequencing at the forefront of understanding human health, the partnership will aim to explore and
demonstrate potential applications of gut microbiome profiling by combining Illumina’s established credibility and
global reach in NGS with Microba’s progressive analytical services,” she said.
With current projects including the exploration of treatments for Parkinson’s disease at the University of Queensland
and the study of faecal microbiome transplants (FMT) used in the treatment of depression with the Food and Mood Centre,
it’s expected that the partnership will increase the uptake of high-quality microbiome research to enable new
discoveries important to human health.